Petros Pharmaceuticals Business Summary

Petros Pharmaceuticals, Inc. (PTPI) operates as a specialty pharmaceutical company that generates revenue through the commercialization of men’s health therapeutics and the licensing of proprietary digital health technologies. The company’s business is divided into three primary segments: Prescription Therapeutics, centered on its flagship erectile dysfunction drug Stendra (avanafil); Medical Devices, which markets vacuum erection devices; and an emerging Technology/SaaS platform. This strategic pivot focuses on a Software as a Medical Device (SaMD) platform that utilizes artificial intelligence and big data to streamline the FDA’s prescription-to-over-the-counter (Rx-to-OTC) switch process. Within the micro-cap pharmaceutical landscape, Petros competes with firms such as Lipella Pharmaceuticals, ProPhase Labs, and Windtree Therapeutics, positioning itself as a technology-driven enabler for the $38 billion self-care market rather than a traditional drug manufacturer. Petros was formed in December 2020 through the strategic merger of Neurotrope, Inc. and Metuchen Pharmaceuticals LLC. The leadership team is headed by Fady Boctor, who serves as President and Chief Commercial Officer, bringing over 20 years of pharmaceutical experience from major firms including Novartis and Endo Pharmaceuticals. The financial operations are managed by Mitchell S. Arnold, Vice President of Finance and Chief Accounting Officer, and Robert Weinstein, who serves as Interim Chief Financial Officer with a 40-year background in healthcare investment banking and corporate finance. The company’s board is led by Chairman Joshua Silverman and includes independent directors Bruce Bernstein and Wayne Walker. Notable institutional backing includes the Jane Street Group, reflecting the company’s continued presence in the public equity markets as it executes its technology-centric transformation.